Region Kronoberg

At Region Kronoberg, cancer research focuses on improving treatment for several major malignancies, including breast cancer, melanoma, prostate cancer, gastric cancer, and bladder cancer. These trials are designed to test new therapies, refine perioperative and adjuvant care, and better match treatment to tumor biology.

• Studies in HER2-positive, HR-positive, and triple-negative breast cancer are evaluating newer treatment combinations and approaches to improve response and disease control.
• Research in melanoma is examining whether shorter immunotherapy after surgery can maintain effectiveness while reducing treatment burden.
• Trials in prostate cancer and bladder cancer are exploring biomarker-guided treatment and ways to improve recurrence-free survival.
• Gastrointestinal oncology work includes studies in resectable gastric and gastroesophageal junction adenocarcinoma to evaluate perioperative treatment effectiveness.

This portfolio reflects a strong emphasis on precision oncology, with research aimed at improving survival, tailoring therapy, and optimizing outcomes for patients with advanced or early-stage cancer.

Clinical trials at this site also address cardiovascular disease, chronic kidney disease, atrial fibrillation, hypertension, type 2 diabetes, and dyslipidemia. The main goal is to improve prevention of serious complications and to evaluate whether newer treatment strategies can reduce long-term risk.

• Research in CKD stage 5 with atrial fibrillation is studying stroke prevention while balancing bleeding risk.
• Trials in acute myocardial infarction are assessing whether intensified lipid management can lower the risk of repeat events and death.
• Studies in type 2 diabetes and hypertension are testing combinations of newer medicines to improve cardiovascular and kidney outcomes.
• Kidney-focused research is also evaluating treatments intended to slow loss of kidney function and reduce heart-related complications.

The cardiovascular and metabolic program combines risk reduction, kidney protection, and cardiometabolic care, offering research that is highly relevant to patients with multiple chronic conditions.

The site conducts studies on common and clinically important bacterial infections, including acute tonsillitis, febrile urinary tract infection, and HPV infection and related cervical disease. These trials are aimed at improving treatment decisions, reducing unnecessary antibiotic use, and supporting better infection control.

• In acute tonsillitis, researchers are comparing antibiotic treatment with no antibiotic use to see whether symptoms can resolve just as well without routine antibiotics.
• For febrile urinary tract infection, the focus is on whether oral step-down treatment can provide effective follow-up care.
• HPV screening and vaccination research is exploring strategies to accelerate elimination of infection and prevent cervical cancer.
• Additional work addresses infection-related conditions in both outpatient and hospital settings to improve everyday clinical care.

This area highlights a practical focus on antimicrobial stewardship, prevention, and better management of infections that affect adults in routine healthcare.

Urologic research at Kirurgmottagningen, Centrallasarettet Växjö includes studies of renal and ureteral conditions, prostate cancer, upper urinary tract surgery, and non-muscle invasive bladder cancer. The trials are designed to improve symptom control, surgical recovery, and recurrence prevention.

• Surgical research is evaluating ways to improve recovery after robot-assisted upper urinary tract surgery.
• Cancer-related studies are examining whether adjuvant treatment can reduce recurrence in bladder cancer.
• Other work addresses renal and ureteral tumors, nephrolithiasis, and renal reflux to support better patient management.

Overall, the urology portfolio combines oncology and benign urologic disease research, with a clear emphasis on improving recovery, reducing recurrence, and refining postoperative care.

Research in this area includes labour induction and HPV-related cervical disease, reflecting interest in both maternity care and women’s cancer prevention. The studies aim to improve safety, effectiveness, and public health outcomes.

• Outpatient labour induction research is assessing whether care outside the hospital can be as safe and effective as inpatient management.
• HPV vaccination and screening studies are focused on reducing infection and preventing cervical cancer.
• Work in female urogenital diseases also connects to broader reproductive health and cancer prevention efforts.

This field combines maternal care with preventive gynecologic research, supporting better pathways for women across different stages of care.

The trial portfolio also touches on respiratory tract disease and broader internal medicine topics, including infection-related upper airway conditions and chronic disease management. These studies are generally aimed at improving everyday treatment choices and patient-centered outcomes.

• Research involving tonsillitis examines whether less antibiotic use can still provide good symptom relief.
• Some studies overlap with metabolic and cardiovascular care, reflecting the complex needs of patients with multiple chronic illnesses.
• The site’s work emphasizes practical questions that can directly inform routine clinical decision-making.

This area shows how the hospital contributes to real-world clinical research beyond specialty oncology and cardiometabolic studies.